A peptidyl-glucosamine derivative affects IKKα kinase activity in human chondrocytes

Arthritis Research and Therapy

Volumn 12, Issue 1, 2010, Pages

  Scotto d'Abusco, Anna ^a   Politi, Laura ^a   Giordano, Cesare ^a   Scandurra, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (N ACETYL)PHENYLALANYLAMIDO 2 DEOXY BETA DEXTRO GLUCOSE; GLUCOSAMINE; GLUCOSAMINE DERIVATIVE; HISTONE H3; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHUK PROTEIN, HUMAN; DRUG DERIVATIVE; I KAPPA B KINASE;

ARTICLE; CARTILAGE CELL; CELLULAR DISTRIBUTION; CHONDROSARCOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL NUCLEUS; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION PROFILING; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT;

BLOTTING, WESTERN; CELL NUCLEUS; CHONDROCYTES; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GLUCOSAMINE; HUMANS; I-KAPPA B KINASE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICROSCOPY, CONFOCAL; NF-KAPPA B; PROTEIN TRANSPORT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77649317886     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2920     Document Type: Article

References (41)

1. Richette P, Bardin T. Structure-modifying agents for osteoarthritis: an update. Joint Bone Spine 2004, 71:18-23. 10.1016/S1297-319X(03)00129-5, 14769516.
2. Shikhman AR, Kuhn K, Alaaeddine N, Lotz M. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol 2001, 166:5155-5160.
3. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, Fournel-Gigleux S, Ouzzine M. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum 2001, 44:351-360. 10.1002/1529-0131(200102)44:2<351::AID-ANR53>3.0.CO;2-M, 11229466.
4. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003, 11:424-432. 10.1016/S1063-4584(03)00052-9, 12801482.
5. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 2004, 1030:578-586. 10.1196/annals.1329.067, 15659840.
6. Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001, 44:2539-2547. 10.1002/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T, 11710710.
7. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gosset C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256. 10.1016/S0140-6736(00)03610-2, 11214126.
8. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulphate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123. 10.1001/archinte.162.18.2113, 12374520.
9. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808. 10.1056/NEJMoa052771, 16495392.
10. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, Harris CL, Singer NG, Bradley JD, Silver D, Jackson CG, Lane NE, Oddis CV, Wolfe F, Lisse J, Furst DE, Reda DJ, Moskowitz RW, Williams HJ, Clegg DO. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008, 58:3183-3191. 10.1002/art.23973, 18821708.
11. Toegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB, Gabor F, Viernstein H. Comparison between chondroprotective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage 2008, 16:1205-1212. 10.1016/j.joca.2008.01.013, 18321735.
12. Scotto d'Abusco A, Corsi A, Grillo MG, Cicione C, Calamia V, Panzini G, Sansone A, Giordano C, Politi L, Scandurra R. Effects of intra-articular administration of glucosamine and a peptidyl-glucosamine derivative in a rabbit model of experimental osteoarthritis: a pilot study. Rheumatol Int 2008, 28:437-443. 10.1007/s00296-007-0463-x, 17924112.
13. Scotto d'Abusco A, Cicione C, Calamia V, Negri R, Giordano C, Grigolo B, Politi L, Scandurra R. Glucosamine and its N-acetyl-phenylalanine derivative prevent TNF-alpha-induced transcriptional activation in human chondrocytes. Clin Exp Rheumatol 2007, 25:847-852.
14. Scotto d'Abusco A, Calamia V, Cicione C, Grigolo B, Politi L, Scandurra R. Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther 2007, 9:R104. 10.1186/ar2307, 2212570, 17925024.
15. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
16. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008, 8:837-848. 10.1038/nri2423, 18927578.
17. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 2006, 25:6706-6716. 10.1038/sj.onc.1209933, 17072323.
18. Hansberger MW, Campbell JA, Danthi P, Arrate P, Pennington KN, Marcu KB, Ballard DW, Dermody TS. IkappaB kinase subunits alpha and gamma are required for activation of NF-kappaB and induction of apoptosis by mammalian reovirus. J Virol 2007, 81:1360-1371. 10.1128/JVI.01860-06, 1797491, 17121808.
19. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003, 423:659-663. 10.1038/nature01648, 12789343.
20. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003, 423:655-659. 10.1038/nature01576, 12789342.
21. Massa PE, Li X, Hanidu A, Siamas J, Pariali M, Pareja J, Savitt AG, Catron KM, Li J, Marcu KB. Gene expression profiling in conjunction with physiological rescues of IKKalpha-null cells with wild type or mutant IKKalpha reveals distinct classes of IKKalpha/NF-kappaB-dependent genes. J Biol Chem 2005, 280:14057-14069. 10.1074/jbc.M414401200, 1226413, 15695520.
22. Olivotto E, Borzi RM, Vitellozzi R, Pagani S, Facchini A, Battistelli M, Penzo M, Li X, Flamigni F, Li J, Falcieri E, Facchini A, Marcu KB. Differential requirements for IKKalpha and IKKbeta in the differentiation of primary human osteoarthritic chondrocytes. Arthritis Rheum 2008, 58:227-239. 10.1002/art.23211, 18163512.
23. Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001, 29:4361-4372. 10.1093/nar/29.21.4361, 60184, 11691923.
24. Giordano C, Gallina C, Consalvi V, Scandurra R. Synthesis and properties of D-glucosamine N-peptidyl derivatives as substrate analog inhibitors of papain and cathepsin B. Eur J Med Chem 1991, 26:753-762.
25. Park GY, Wang X, Hu N, Pedchenko TV, Blackwell TS, Christman JW. NIK is involved in nucleosomal regulation by enhancing histone H3 phosphorylation by IKKalpha. J Biol Chem 2006, 281:18684-18690. 10.1074/jbc.M600733200, 16675465.
26. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006, 2006(357):re13. 10.1126/stke.3572006re13, 17047224.
27. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 2006, 25:6717-6730. 10.1038/sj.onc.1209937, 17072324.
28. Gloire G, Horion J, El Mjiyad N, Bex F, Chariot A, Dejardin E, Piette J. Promoter-dependent effect of IKKalpha on NF-kappaB/p65 DNA binding. J Biol Chem 2007, 282:21308-21318. 10.1074/jbc.M610728200, 17537731.
29. Gloire G, Dejardin E, Piette J. Extending the nuclear roles of IkappaB kinase subunits. Biochem Pharmacol 2006, 72:1081-1089. 10.1016/j.bcp.2006.06.017, 16846590.
30. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol 2005, 6:439-445. 10.1038/ni1196, 15843800.
31. Hoberg JE, Yeung F, Mayo MW. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell 2004, 16:245-255. 10.1016/j.molcel.2004.10.010, 15494311.
32. Hoberg JE, Popko AE, Ramsey CS, Mayo MW. IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol 2006, 26:457-471. 10.1128/MCB.26.2.457-471.2006, 1346914, 16382138.
33. Sil AK, Maeda S, Sano Y, Roop DR, Karin M. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 2004, 428:660-664. 10.1038/nature02421, 15071597.
34. Lawrence T, Bebien M. IKKalpha in the regulation of inflammation and adaptive immunity. Biochem Soc Trans 2007, 35:270-272. 10.1042/BST0350270, 17371257.
35. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009, 19:404-413. 10.1016/j.tcb.2009.05.006, 19648011.
36. Jeong WS, Kim IW, Hu R, Kong AN. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 2004, 21:661-670. 10.1023/B:PHAM.0000022413.43212.cf, 15139523.
37. Prawan A, Saw CL, Khor TO, Keum YS, Yu S, Hu L, Kong AN. Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling. Chem Biol Interact 2009, 179:202-211. 10.1016/j.cbi.2008.12.014, 19159619.
38. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
39. Yan F, Polk DB. Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. J Biol Chem 1999, 274:36631-36636. 10.1074/jbc.274.51.36631, 10593965.
40. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006, 69:195-206.
41. Hoffmann A, Leung TH, Baltimore D. Genetic analysis of NF-kappaB/Rel transcription factors defines functional specificities. EMBO J 2003, 22:5530-5539. 10.1093/emboj/cdg534, 213788, 14532125.